ClinicalTrials.gg
CompletedNCT00627458Updated Jun 6, 2018Results posted

Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine

A Phase 2 interventional study of Infanrix Hexa in Acellular Pertussis, Diphtheria and Poliomyelitis, sponsored by GlaxoSmithKline. Completed at 6 sites in Finland. Open to participants aged 16 Months to 20 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-06.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
403
Allocation
Non-randomized
Ages
16 Months to 20 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Diphtheria — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Diphtheria.

Enrollment
10th of 15
403 · median 494
Started
2008
with 2 others
Phase 2
2 of 15
none open now
Registered
5th of 15
by date
Lead sponsor
14 of 15
GlaxoSmithKline

Among the 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Diphtheria, this one is the 10th largest by enrollment, is one of 3 that started in 2008, is one of 2 in phase 2, and was the 5th registered.

Diphtheria

268 studies on the registry are indexed under Diphtheria; 18 are open to participants now.

Browse Diphtheria studies →

Open to participants now

None of the 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Diphtheria is open now. The open studies under Diphtheria, anywhere →

About diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 11 Diphtheria studies recruiting now, 2 (18%) set no upper age limit and 9 (82%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.

This study: 16 Months to 20 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Diphtheria as a file.
02

Study summary

The purpose of this booster study is to evaluate, in subjects primed in the primary study 106786, the persistence, at the time of the booster vaccination, of antibodies elicited by the different formulation of DTPa-HBV-IPV/ Hib vaccine (Infanrix Hexa TM). The study will also evaluate the immune response of these subjects to a DTPa-HBV-IPV/Hib booster. This protocol posting deals with the objectives and outcome measures of the booster phase. The objectives and outcomes measures of the primary phase are presented in a separate protocol posting (NCT = 00376779).

Read the detailed description

This protocol posting has been updated in order to comply with the FDA AA, Sep 2007.

03

Conditions studied

  • Acellular Pertussis
  • Diphtheria
  • Poliomyelitis
  • Haemophilus Influenzae Type b
  • Tetanus
  • Hepatitis B

Keywords

  • Hexavalent vaccine
  • Booster
04

Who can participate

Ages eligible
16 Months to 20 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol
  • Subjects must have completed the full three-dose primary vaccination course with one of the formulations of the DTPa--IPV/Hib vaccine in primary study 106786.
  • A male or female between, and including, 16 and 20 months of age at the time of booster vaccination.
  • Written obtained from the parent or guardian of the subject
  • Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the booster dose of study vaccine, or planned use during the study period.
  • Chronic administration of or other immune-modifying drugs within six months prior to the booster vaccine dose.
  • Participation in another clinical study, between the primary study 106786 and the present booster study, or at any time during the study, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Planned administration or administration of a vaccine not foreseen by the study protocol during the period starting 30 days before the administration of the booster dose and ending 30 days after the booster dose.
  • Evidence of previous diphtheria, tetanus, pertussis, polio, and/or Hib booster vaccination or disease since the conclusion visit of study 106786.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on physical examination.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
  • Acute disease at the time of enrolment.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the booster dose or planned administration during the study period.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
403 participants (actual)

Study arms

  • Experimental
    INFANRIX HEXA PF GROUP

    Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-free (PF) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.

    Biological: Infanrix Hexa

  • Experimental
    INFANRIX HEXA PC GROUP

    Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-containing (PC) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.

    Biological: Infanrix Hexa

  • Active comparator
    CONTROL GROUP

    Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the licensed formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.

    Biological: Infanrix Hexa

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids

    A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).

    Time frame: Before the booster administration (At Month 0)

  2. Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids

    A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 IU/mL.

    Time frame: One month after the booster vaccination (At Month 1)

  3. Number of Seroprotected Subjects Against Hepatitis B Surface Antigen (HBs)

    A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 milli international units per milliliter (mIU/mL). Also reported are the number of participants with anti-HBs antibody concentrations ≥ 100 mIU/mL.

    Time frame: Before the booster vaccination (At Month 0)

  4. Number of Seroprotected Subjects Against Hepatitis B Surface Antigen (HBs)

    A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL. Also reported are the number of participants with anti-HBs antibody concentrations ≥ 100 mIU/mL.

    Time frame: One month after the booster vaccination (At Month 1)

  5. Number of Seroprotected Subjects Against Poliovirus Type 1, Type 2 and Type 3

    A seroprotected subject was defined as a subject with anti-Polio 1, 2 and 3 antibody titers ≥ the value of 8.

    Time frame: Before the booster vaccination (At Month 0)

  6. Number of Seroprotected Subjects Against Poliovirus Type 1, Type 2 and Type 3

    A seroprotected subject was defined as a subject with anti-Polio 1, 2 and 3 antibody titers ≥ the value of 8.

    Time frame: One month after the booster vaccination (At Month 1)

  7. Number of Seroprotected Subjects Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN)

    A seroprotected subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

    Time frame: Before the booster vaccination (At Month 0)

  8. Number of Seroprotected Subjects Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN)

    A seroprotected subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL.

    Time frame: One month after the booster vaccination (At Month 1)

  9. Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP)

    A seroprotected subject was defined as a subject with anti-PRP antibody concentrations greater than or equal to (≥) 0.15 micrograms per milliliter (µg/mL). Also reported are the number of participants with anti-PRP antibody concentrations ≥ 1.0 µg/mL.

    Time frame: Before the booster vaccination (At Month 0)

  10. Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP)

    A seroprotected subject was defined as a subject with anti-PRP antibody concentrations ≥ 0.15 µg/mL. Also reported are the number of participants with anti-PRP antibody concentrations ≥ 1.0 µg/mL.

    Time frame: One month after the booster vaccination (At Month 1)

  11. Number of Subjects With a Vaccine Response to PT, FHA and PR

    Vaccine response was defined as the appearance of antibodies in subjects who were initially seronegative (S-) \[i.e. with concentrations lower than (\<) the cut-off value\] or at least doubling of pre-vaccination antibody concentrations in subjects who were initially seropositive (S+) \[i.e. with concentrations greater than (\>) the cut-off value).

    Time frame: One month after the booster vaccination (At Month 1)

  12. Anti-D and Anti-T Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.

    Time frame: Before the booster vaccination (At Month 0)

  13. Anti-D and Anti-T Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.

    Time frame: One month after the booster vaccination (At Month 1)

  14. Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.

    Time frame: Before the booster vaccination (At Month 0)

  15. Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.

    Time frame: One month after the booster vaccination (At Month 1)

  16. Anti-HBs Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.

    Time frame: Before the booster vaccination (At Month 0)

  17. Anti-HBs Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.

    Time frame: One month after the booster vaccination (At Month 1)

  18. Anti-poliovirus Type 1, Type 2 and Type 3 Antibody Titers

    Antibody titers were presented as geometric mean titers (GMTs).

    Time frame: Before the booster vaccination (At Month 0)

  19. Anti-poliovirus Type 1, Type 2 and Type 3 Antibody Titers

    Antibody titers were presented as geometric mean titers (GMTs).

    Time frame: One month after the booster vaccination (At Month 1)

  20. Anti-PRP Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in micrograms per milliliter (µg/mL).

    Time frame: Before the booster vaccination (At Month 0)

  21. Anti-PRP Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in µg/mL.

    Time frame: One month after the booster vaccination (At Month 1)

Secondary outcomes

  1. Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids

    A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations ≥ 0.1 IU/mL .

    Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination

  2. Number of Seroprotected Subjects Against Hepatitis B Surface Antigen (HBs)

    A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL. Also reported are the number of participants with anti-HBs antibody concentrations ≥ 100 mIU/mL.

    Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination

  3. Number of Seroprotected Subjects Against Poliovirus Type 1, Type 2 and Type 3

    A seroprotected subject was defined as a subject with anti-polio 1, 2 and 3 antibody titers ≥ the value of 8.

    Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination

  4. Number of Seroprotected Subjects Against PT, FHA and PRN

    A seroprotected subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL .

    Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination

  5. Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP)

    A seroprotected subject was defined as a subject with anti-PRP antibody concentrations ≥ 0.15 μg/mL. Also reported are the number of participants with anti-PRP antibody concentrations ≥ 1.0 µg/mL.

    Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination

  6. Anti-D and Anti-T Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.

    Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination

  7. Anti-PT, Anti-FHA, Anti-PRN Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.

    Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination

  8. Anti-HBs Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.

    Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination

  9. Anti-poliovirus Type 1, 2 and 3 Antibody Titers

    Antibody titers were presented as geometric mean titers (GMTs).

    Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination

  10. Anti-PRP Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in µg/mL.

    Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination

  11. Number of Subjects With a Vaccine Response to PT, FHA and PR

    Vaccine response was defined as the appearance of antibodies in subjects who were initially seronegative (S-) (i.e. with concentrations \< cut-off value) or at least doubling of pre-vaccination antibody concentrations in subjects who were initially seropositive (S+) (i.e. with concentrations \> cut-off value).

    Time frame: One month after the booster dose (At Month 1)

  12. Number of Subjects With Any Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.

    Time frame: During the 4-day (Days 0-3) follow-up period after the booster vaccination

  13. Number of Subjects With Any Solicited General Symptoms

    Assessed solicited general symptoms were drowsiness, fever \[defined as rectal temperature equal to or above (≥) 38.0 degrees Celsius (°C)\], irritability and loss of appetite. Any = occurrence of the symptom regardless of intensity grade.

    Time frame: During the 4-day (Days 0-3) follow-up period after the booster vaccination

  14. Number of Subjects With Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

    Time frame: During the 31-day (Day 0-30) follow-up period after the booster vaccination

  15. Number of Subjects With Serious Adverse Events (SAEs)

    Assessed SAEs include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From Month 0 to Month 1, during the entire study period

  16. Number of Subjects Reporting Concomitant Medications

    Time frame: During the 4-day (Days 0-3) follow-up period after the booster vaccination

07

Results

Posted Jun 26, 2017

Participant flow

Participant flow — Overall Study
MilestoneInfanrix Hexa PF GroupInfanrix Hexa PC GroupControl Group
Started127137139
Completed123130133
Not completed476
Withdrew: Migrated from study area101
Withdrew: Withdrawal by subject265
Withdrew: Lost to follow-up110

Outcome measures

PrimaryNumber of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids

A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).

Time frame:
Before the booster administration (At Month 0)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids
ParticipantsInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-D2235
Anti-T93103
PrimaryNumber of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids

A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 IU/mL.

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids
ParticipantsInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-D112118
Anti-T113118
PrimaryNumber of Seroprotected Subjects Against Hepatitis B Surface Antigen (HBs)

A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 milli international units per milliliter (mIU/mL). Also reported are the number of participants with anti-HBs antibody concentrations ≥ 100 mIU/mL.

Time frame:
Before the booster vaccination (At Month 0)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Hepatitis B Surface Antigen (HBs)
ParticipantsInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-HBs ≥ 10 mIU/mL106112
Anti HBs ≥ 100 mIU/mL5554
PrimaryNumber of Seroprotected Subjects Against Hepatitis B Surface Antigen (HBs)

A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL. Also reported are the number of participants with anti-HBs antibody concentrations ≥ 100 mIU/mL.

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Hepatitis B Surface Antigen (HBs)
ParticipantsInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-HBs ≥ 10 mIU/mL110117
Anti HBs ≥ 100 mIU/mL105113
PrimaryNumber of Seroprotected Subjects Against Poliovirus Type 1, Type 2 and Type 3

A seroprotected subject was defined as a subject with anti-Polio 1, 2 and 3 antibody titers ≥ the value of 8.

Time frame:
Before the booster vaccination (At Month 0)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Poliovirus Type 1, Type 2 and Type 3
ParticipantsInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-polio 16776
Anti-polio 24851
Anti-polio 35877
PrimaryNumber of Seroprotected Subjects Against Poliovirus Type 1, Type 2 and Type 3

A seroprotected subject was defined as a subject with anti-Polio 1, 2 and 3 antibody titers ≥ the value of 8.

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Poliovirus Type 1, Type 2 and Type 3
ParticipantsInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-polio 1110117
Anti-polio 2110117
Anti-polio 3111117
PrimaryNumber of Seroprotected Subjects Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN)

A seroprotected subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

Time frame:
Before the booster vaccination (At Month 0)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN)
ParticipantsInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-PT8081
Anti-FHA106107
Anti-PRN8186
PrimaryNumber of Seroprotected Subjects Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN)

A seroprotected subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL.

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN)
ParticipantsInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-PT111118
Anti-FHA112118
Anti-PRN113117
PrimaryNumber of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP)

A seroprotected subject was defined as a subject with anti-PRP antibody concentrations greater than or equal to (≥) 0.15 micrograms per milliliter (µg/mL). Also reported are the number of participants with anti-PRP antibody concentrations ≥ 1.0 µg/mL.

Time frame:
Before the booster vaccination (At Month 0)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP)
ParticipantsInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-PRP ≥ 0.15μg/mL7187
Anti-PRP ≥ 1.0μg/mL1523
PrimaryNumber of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP)

A seroprotected subject was defined as a subject with anti-PRP antibody concentrations ≥ 0.15 µg/mL. Also reported are the number of participants with anti-PRP antibody concentrations ≥ 1.0 µg/mL.

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP)
ParticipantsInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-PRP ≥ 0.15 µg/mL112119
Anti-PRP ≥ 1.0 µg/mL111117
PrimaryNumber of Subjects With a Vaccine Response to PT, FHA and PR

Vaccine response was defined as the appearance of antibodies in subjects who were initially seronegative (S-) \[i.e. with concentrations lower than (\<) the cut-off value\] or at least doubling of pre-vaccination antibody concentrations in subjects who were initially seropositive (S+) \[i.e. with concentrations greater than (\>) the cut-off value).

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With a Vaccine Response to PT, FHA and PR
ParticipantsInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-PT, S-2930
Anti-PT, S+7881
Anti-PT, Total107111
Anti-FHA, S-44
Anti-FHA, S+104106
Anti-FHA, Total108110
Anti-PRN, S-3130
Anti-PRN, S+8185
Anti-PRN, Total112115
PrimaryAnti-D and Anti-T Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.

Time frame:
Before the booster vaccination (At Month 0)
Reported as:
Geometric mean · IU/mL
Anti-D and Anti-T Antibody Concentrations
IU/mLInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-D0.064 (0.058 to 0.071)0.069 (0.062 to 0.076)
Anti-T0.216 (0.184 to 0.254)0.248 (0.213 to 0.289)
PrimaryAnti-D and Anti-T Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Geometric mean · IU/mL
Anti-D and Anti-T Antibody Concentrations
IU/mLInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-D2.237 (1.877 to 2.666)2.242 (1.868 to 2.689)
Anti-T9.799 (8.39 to 11.444)9.136 (7.838 to 10.648)
PrimaryAnti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.

Time frame:
Before the booster vaccination (At Month 0)
Reported as:
Geometric mean · EL.U/mL
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
EL.U/mLInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-PT7.8 (6.7 to 9.1)7 (6.1 to 8.1)
Anti-FHA21.7 (18.1 to 25.9)22.1 (18.5 to 26.2)
Anti-PRN8.6 (7.1 to 10.3)8.7 (7.3 to 10.2)
PrimaryAnti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Geometric mean · EL.U/mL
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
EL.U/mLInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-PT150.9 (132.9 to 171.2)117.1 (101.5 to 135)
Anti-FHA609.6 (534.1 to 695.7)533.7 (463 to 615.1)
Anti-PRN308.5 (261.3 to 364.2)311.7 (260.3 to 373.2)
PrimaryAnti-HBs Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.

Time frame:
Before the booster vaccination (At Month 0)
Reported as:
Geometric mean · mIU/mL
Anti-HBs Antibody Concentrations
mIU/mLInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-HBs Antibody Concentrations84.3 (65.7 to 108.2)86.2 (67.8 to 109.6)
PrimaryAnti-HBs Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Geometric mean · mIU/mL
Anti-HBs Antibody Concentrations
mIU/mLInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-HBs Antibody Concentrations3291.7 (2373.6 to 4565)3528.1 (2546.1 to 4888.9)
PrimaryAnti-poliovirus Type 1, Type 2 and Type 3 Antibody Titers

Antibody titers were presented as geometric mean titers (GMTs).

Time frame:
Before the booster vaccination (At Month 0)
Reported as:
Geometric mean · Titers
Anti-poliovirus Type 1, Type 2 and Type 3 Antibody Titers
TitersInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-polio 112.9 (10.3 to 16.3)15.2 (12.3 to 18.9)
Anti-polio 29.1 (7.3 to 11.3)8.7 (7.2 to 10.5)
Anti-polio 39.5 (7.9 to 11.6)16 (12.6 to 20.4)
PrimaryAnti-poliovirus Type 1, Type 2 and Type 3 Antibody Titers

Antibody titers were presented as geometric mean titers (GMTs).

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Geometric mean · Titers
Anti-poliovirus Type 1, Type 2 and Type 3 Antibody Titers
TitersInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-polio 1726.3 (560.4 to 941.4)942.4 (734.1 to 1209.7)
Anti-polio 2712.8 (529.1 to 960.4)812.9 (632.8 to 1044.3)
Anti-polio 3780 (591 to 1029.3)1145.8 (891.6 to 1472.5)
PrimaryAnti-PRP Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in micrograms per milliliter (µg/mL).

Time frame:
Before the booster vaccination (At Month 0)
Reported as:
Geometric mean · µg/mL
Anti-PRP Antibody Concentrations
µg/mLInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-PRP Antibody Concentrations0.249 (0.199 to 0.31)0.314 (0.252 to 0.392)
PrimaryAnti-PRP Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in µg/mL.

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Geometric mean · µg/mL
Anti-PRP Antibody Concentrations
µg/mLInfanrix Hexa PF GroupInfanrix Hexa PC Group
Anti-PRP Antibody Concentrations36.866 (28.61 to 47.504)35.318 (27.447 to 45.445)
SecondaryNumber of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids

A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations ≥ 0.1 IU/mL .

Time frame:
Before (Month 0) and one month after (Month 1) the booster vaccination
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids
ParticipantsControl Group
Anti-D, M040
Anti-D, M1119
Anti-T, M095
Anti-T, M1119
SecondaryNumber of Seroprotected Subjects Against Hepatitis B Surface Antigen (HBs)

A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL. Also reported are the number of participants with anti-HBs antibody concentrations ≥ 100 mIU/mL.

Time frame:
Before (Month 0) and one month after (Month 1) the booster vaccination
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Hepatitis B Surface Antigen (HBs)
ParticipantsControl Group
Anti-HBs ≥ 10 mIU/mL, M0106
Anti-HBs ≥ 10 mIU/mL, M1118
Anti HBs ≥ 100 mIU/mL, M067
Anti HBs ≥ 100 mIU/mL, M1114
SecondaryNumber of Seroprotected Subjects Against Poliovirus Type 1, Type 2 and Type 3

A seroprotected subject was defined as a subject with anti-polio 1, 2 and 3 antibody titers ≥ the value of 8.

Time frame:
Before (Month 0) and one month after (Month 1) the booster vaccination
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Poliovirus Type 1, Type 2 and Type 3
ParticipantsControl Group
Anti-polio 1, M084
Anti-polio 1, M1112
Anti-polio 2, M056
Anti-polio 2, M1112
Anti-polio 3, M082
Anti-polio 3, M1113
SecondaryNumber of Seroprotected Subjects Against PT, FHA and PRN

A seroprotected subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL .

Time frame:
Before (Month 0) and one month after (Month 1) the booster vaccination
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against PT, FHA and PRN
ParticipantsControl Group
Anti-PT, M093
Anti-PT, M1119
Anti-FHA, M0109
Anti-FHA, M1119
Anti-PRN, M099
Anti-PRN, M1119
SecondaryNumber of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP)

A seroprotected subject was defined as a subject with anti-PRP antibody concentrations ≥ 0.15 μg/mL. Also reported are the number of participants with anti-PRP antibody concentrations ≥ 1.0 µg/mL.

Time frame:
Before (Month 0) and one month after (Month 1) the booster vaccination
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP)
ParticipantsControl Group
Anti-PRP ≥ 0.15 μg/mL, M092
Anti-PRP ≥ 0.15 μg/mL, M1119
Anti-PRP ≥ 1.0 μg/mL, M032
Anti-PRP ≥ 1.0 μg/mL, M1118
SecondaryAnti-D and Anti-T Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.

Time frame:
Before (Month 0) and one month after (Month 1) the booster vaccination
Reported as:
Geometric mean · IU/mL
Anti-D and Anti-T Antibody Concentrations
IU/mLControl Group
Anti-D, M00.084 (0.073 to 0.097)
Anti-D, M13.952 (3.365 to 4.642)
Anti-T, M00.261 (0.219 to 0.31)
Anti-T, M110.833 (9.505 to 12.347)
SecondaryAnti-PT, Anti-FHA, Anti-PRN Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.

Time frame:
Before (Month 0) and one month after (Month 1) the booster vaccination
Reported as:
Geometric mean · EL.U/mL
Anti-PT, Anti-FHA, Anti-PRN Antibody Concentrations
EL.U/mLControl Group
Anti-PT, M08.9 (7.7 to 10.3)
Anti-PT, M1153.7 (135.1 to 174.9)
Anti-FHA, M033.7 (27.6 to 41.1)
Anti-FHA, M1791.9 (708.8 to 884.8)
Anti-PRN, M015.3 (12.6 to 18.5)
Anti-PRN, M1564.1 (489.5 to 650.1)
SecondaryAnti-HBs Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.

Time frame:
Before (Month 0) and one month after (Month 1) the booster vaccination
Reported as:
Geometric mean · mIU/mL
Anti-HBs Antibody Concentrations
mIU/mLControl Group
Anti-HBs, M0139.8 (107.2 to 182.3)
Anti-HBs, M16132.7 (4587.8 to 8197.9)
SecondaryAnti-poliovirus Type 1, 2 and 3 Antibody Titers

Antibody titers were presented as geometric mean titers (GMTs).

Time frame:
Before (Month 0) and one month after (Month 1) the booster vaccination
Reported as:
Geometric mean · Titers
Anti-poliovirus Type 1, 2 and 3 Antibody Titers
TitersControl Group
Anti-polio 1, M021.6 (17.1 to 27.4)
Anti-polio 1, M11288.8 (1029.1 to 1614)
Anti-polio 2, M011.8 (9.2 to 15)
Anti-polio 2, M11231 (961 to 1576.9)
Anti-polio 3, M021.3 (16.4 to 27.7)
Anti-polio 3, M11794.8 (1426.8 to 2257.7)
SecondaryAnti-PRP Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in µg/mL.

Time frame:
Before (Month 0) and one month after (Month 1) the booster vaccination
Reported as:
Geometric mean · µg/mL
Anti-PRP Antibody Concentrations
µg/mLControl Group
Anti-PRP, M00.487 (0.383 to 0.62)
Anti-PRP, M177.087 (60.224 to 98.672)
SecondaryNumber of Subjects With a Vaccine Response to PT, FHA and PR

Vaccine response was defined as the appearance of antibodies in subjects who were initially seronegative (S-) (i.e. with concentrations \< cut-off value) or at least doubling of pre-vaccination antibody concentrations in subjects who were initially seropositive (S+) (i.e. with concentrations \> cut-off value).

Time frame:
One month after the booster dose (At Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With a Vaccine Response to PT, FHA and PR
ParticipantsControl Group
Anti-PT, S-17
Anti-PT, S+93
Anti-PT, Total110
Anti-FHA, S-0
Anti-FHA, S+105
Anti-FHA, Total105
Anti-PRN, S-12
Anti-PRN, S+98
Anti-PRN, Total110
SecondaryNumber of Subjects With Any Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.

Time frame:
During the 4-day (Days 0-3) follow-up period after the booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any Solicited Local Symptoms
ParticipantsInfanrix Hexa PF GroupInfanrix Hexa PC GroupControl Group
Any Pain747682
Any Redness667994
Any Swelling445360
SecondaryNumber of Subjects With Any Solicited General Symptoms

Assessed solicited general symptoms were drowsiness, fever \[defined as rectal temperature equal to or above (≥) 38.0 degrees Celsius (°C)\], irritability and loss of appetite. Any = occurrence of the symptom regardless of intensity grade.

Time frame:
During the 4-day (Days 0-3) follow-up period after the booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any Solicited General Symptoms
ParticipantsInfanrix Hexa PF GroupInfanrix Hexa PC GroupControl Group
Any Drowsiness504858
Any Fever (Rectal)223431
Any Irritability688678
Any Loss of Appetite374645
SecondaryNumber of Subjects With Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Time frame:
During the 31-day (Day 0-30) follow-up period after the booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Unsolicited Adverse Events (AEs)
ParticipantsInfanrix Hexa PF GroupInfanrix Hexa PC GroupControl Group
Number of Subjects With Unsolicited Adverse Events (AEs)515461
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

Assessed SAEs include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From Month 0 to Month 1, during the entire study period
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsInfanrix Hexa PF GroupInfanrix Hexa PC GroupControl Group
Number of Subjects With Serious Adverse Events (SAEs)121
SecondaryNumber of Subjects Reporting Concomitant Medications
Time frame:
During the 4-day (Days 0-3) follow-up period after the booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects Reporting Concomitant Medications
ParticipantsInfanrix Hexa PF GroupInfanrix Hexa PC GroupControl Group
Any concomitant medication105111116
Any antipyretic343533

Adverse events

Collected over Solicited symptoms: during the 4-day (Days 0-3) period after the booster vaccination. Unsolicited AEs: during the 31-day (Days 0-30) period after the booster vaccination. SAEs: during the entire study period (from Month 0 up to Month 1).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Infanrix Hexa PF Group0/127 (0%)1/127 (0.8%)116/127 (91.3%)
Infanrix Hexa PC Group0/137 (0%)2/137 (1.5%)126/137 (92%)
Control Group0/139 (0%)1/139 (0.7%)129/139 (92.8%)
Most frequent serious events
Most frequent serious events
EventInfanrix Hexa PF GroupInfanrix Hexa PC GroupControl Group
Gastroenteritis rotavirusInfections and infestations1/1271/1370/139
GastroenteritisInfections and infestations0/1271/1370/139
Pneumonia adenoviralInfections and infestations0/1270/1371/139
Most frequent other events
Showing 10 of 14
Most frequent other events
EventInfanrix Hexa PF GroupInfanrix Hexa PC GroupControl Group
RednessGeneral disorders66/12679/13694/138
IrritabilityGeneral disorders68/12686/13678/138
PainGeneral disorders74/12676/13682/138
SwellingGeneral disorders44/12653/13660/138
DrowsinessGeneral disorders50/12648/13658/138
Loss of appetiteGeneral disorders37/12646/13645/138
Fever/(Rectal)General disorders22/12634/13631/138
Otitis mediaInfections and infestations4/1277/13714/139
Injection site indurationGeneral disorders5/1272/13710/139
Upper respiratory tract infectionInfections and infestations9/1278/1376/139

Baseline characteristics

Age, Continuous
Age, Continuous(Months)Infanrix Hexa PF GroupInfanrix Hexa PC GroupControl GroupTotal
Mean17.9 ± 1.1218 ± 1.0317.8 ± 1.1117.90 ± 1.09
Sex: Female, Male
Sex: Female, Male(Participants)Infanrix Hexa PF GroupInfanrix Hexa PC GroupControl GroupTotal
Female566659181
Male717180222
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Infanrix Hexa PF GroupInfanrix Hexa PC GroupControl GroupTotal
Geographic ancestry — White-Caucasian/European heritage125134135394
Geographic ancestry — White-Arabic/North African heritage0112
Geographic ancestry — Not specified2237
08

Study locations

6 sites
  • GSK Investigational Site
    Jarvenpaa, 04400, Finland
  • GSK Investigational Site
    Oulu, 90220, Finland
  • GSK Investigational Site
    Pori, 28100, Finland
  • GSK Investigational Site
    Tampere, 33100, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Vantaa, 01300, Finland
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 8 years 10 months after primary completion. A results delay was requested in May 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2008
First posted
Mar 3, 2008
Start
Feb 1, 2008
Primary completionActual
Aug 18, 2008
CompletionActual
Aug 18, 2008
Results delay requested
May 20, 2009
Results first posted
Jun 26, 2017
Last update
Jun 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00627458
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 3, 2008
Start date
Feb 1, 2008
Primary completion
Aug 18, 2008
Completion
Aug 18, 2008
Results posted
Jun 26, 2017
Last update
Jun 6, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

Start the discussion